Lonza, Portola Pharmaceuticals Sign Manufacturing Agreement
Lonza and Portola Pharmaceuticals have entered into a supply agreement for AndexXa (andexanet alfa), a recombinant protein used in patients on FXa inhibitors who experience a major bleed or need urgent surgery.
On Sept. 5, 2017, Lonza announced a supply agreement with Portola Pharmaceuticals, a biopharmaceutical company specializing in thrombosis and other hematologic diseases, for AndexXa (andexanet alfa), a universal recombinant protein reversal agent for patients on FXa inhibitors who experience a major bleed or need urgent surgery.
Under the terms of the agreement, Lonza will provide Portola with security of supply, extend current manufacturing commitments at its Porrino, Spain facility, and add long-term manufacturing production in Visp, Switzerland for AndexXa. With this agreement, Lonza adds a client to its new modular manufacturing complex, Ibex, launched in July 2017.
The deal strengthens the companies’ relationship after an earlier collaboration for the clinical manufacturing of andexanet alfa announced in 2014. Additionally, in 2016, Portola signed a loan agreement with Bristol-Myers Squibb and Pfizer for the development and commercialization of andexanet alfa in Japan.
Source: Lonza
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
